The Additive Effect of Vitamin K Supplementation and Bisphosphonate on Fracture Risk in Post-menopausal Osteoporosis.
Phase of Trial: Phase II/III
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Menatetrenone (Primary) ; Phytomenadione (Primary) ; Alendronic acid; Bisphosphonates
- Indications Metabolic bone diseases; Postmenopausal osteoporosis
- Focus Therapeutic Use
- Acronyms VITKANDOP
- 31 Jul 2017 Planned number of patients changed from 150 to 105.
- 31 Jul 2017 Planned End Date changed from 30 Apr 2017 to 1 Dec 2019.
- 31 Jul 2017 Planned primary completion date changed from 1 Jun 2013 to 1 Oct 2019.